Brief: Abeona Therapeutics Announces Permanent J-Code For Zevaskyn(Prademagene Zamikeracel)
30/10/2025 16:26
Oct 30 (Reuters) - Abeona Therapeutics Inc ABEO.O: ABEONA THERAPEUTICS® ANNOUNCES PERMANENT J-CODE FOR ZEVASKYN® (PRADEMAGENE ZAMIKERACEL) ABEONA THERAPEUTICS INC - NEW J-CODE J3389 FOR ZEVASKYN EFFECTIVE JANUARY 1, 2026 ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abeona Therapeutics
See all newsBrief: Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx rises after FDA nod for rare disorder drug
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports